JPS626546B2 - - Google Patents

Info

Publication number
JPS626546B2
JPS626546B2 JP53111484A JP11148478A JPS626546B2 JP S626546 B2 JPS626546 B2 JP S626546B2 JP 53111484 A JP53111484 A JP 53111484A JP 11148478 A JP11148478 A JP 11148478A JP S626546 B2 JPS626546 B2 JP S626546B2
Authority
JP
Japan
Prior art keywords
halogen atom
ethanol
group
general formula
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53111484A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5538325A (en
Inventor
Shinsaku Kobayashi
Katsuo Kamoshita
Shigeki Nagai
Takeo Pponda
Kiroku Oda
Katsutoshi Fujii
Takashi Furubayashi
Mikio Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Ube Corp
Original Assignee
Sankyo Co Ltd
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Ube Industries Ltd filed Critical Sankyo Co Ltd
Priority to JP11148478A priority Critical patent/JPS5538325A/ja
Priority to SE7907493A priority patent/SE446337B/sv
Priority to IT68794/79A priority patent/IT1119933B/it
Priority to CA000335246A priority patent/CA1151168A/en
Priority to CH816679A priority patent/CH642361A5/de
Priority to DK377079A priority patent/DK377079A/da
Priority to BE0/197102A priority patent/BE878723A/fr
Priority to GB7931441A priority patent/GB2033894B/en
Priority to FR7922639A priority patent/FR2435248A1/fr
Priority to ES484097A priority patent/ES8100276A1/es
Priority to DE19792936705 priority patent/DE2936705A1/de
Priority to NL7906761A priority patent/NL7906761A/nl
Priority to US06/074,343 priority patent/US4322420A/en
Publication of JPS5538325A publication Critical patent/JPS5538325A/ja
Priority to US06/289,379 priority patent/US4464375A/en
Publication of JPS626546B2 publication Critical patent/JPS626546B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP11148478A 1978-09-11 1978-09-11 4-anilinoquinazoline derivative and its preparation Granted JPS5538325A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP11148478A JPS5538325A (en) 1978-09-11 1978-09-11 4-anilinoquinazoline derivative and its preparation
SE7907493A SE446337B (sv) 1978-09-11 1979-09-10 Nya 4-anilinokinazolinderivat till anvendning som analgetiska och antiinflammatoriska medel samt farmaceutisk komposition derav
IT68794/79A IT1119933B (it) 1978-09-11 1979-09-10 Derivati della 4 anilinochinazolina particolarmente utili come analgesici ed antinfiammatori e procedimento per la loro preparzione
CA000335246A CA1151168A (en) 1978-09-11 1979-09-10 4-anilinoquinazoline derivatives and their preparation
CH816679A CH642361A5 (de) 1978-09-11 1979-09-10 4-anilinochinazolinderivate, ihre herstellung und diese enthaltende pharmazeutische praeparate.
DK377079A DK377079A (da) 1978-09-11 1979-09-10 Fremgangsmaade til fremstilling af 4-anilinoquinazolinderivater
GB7931441A GB2033894B (en) 1978-09-11 1979-09-11 4-anilinoquinayolines
BE0/197102A BE878723A (fr) 1978-09-11 1979-09-11 Derives de 4-anilinoquinazoline, leur procede de preparation et leur application en therapeutique
FR7922639A FR2435248A1 (fr) 1978-09-11 1979-09-11 Derives de 4-anilinoquinazoline, leur procede de preparation et leur application en therapeutique
ES484097A ES8100276A1 (es) 1978-09-11 1979-09-11 Un procedimiento para la preparacion de nuevos derivados de-4-anilinoquinazolinas
DE19792936705 DE2936705A1 (de) 1978-09-11 1979-09-11 Neue 4-anilinochinazolinderivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
NL7906761A NL7906761A (nl) 1978-09-11 1979-09-11 Nieuwe 4-anilinochinazoline verbindingen en hun bereiding.
US06/074,343 US4322420A (en) 1978-09-11 1979-09-11 Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents
US06/289,379 US4464375A (en) 1978-09-11 1981-08-03 4-Anilinoquinazoline compounds and pharmaceutical compositions thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11148478A JPS5538325A (en) 1978-09-11 1978-09-11 4-anilinoquinazoline derivative and its preparation

Publications (2)

Publication Number Publication Date
JPS5538325A JPS5538325A (en) 1980-03-17
JPS626546B2 true JPS626546B2 (en:Method) 1987-02-12

Family

ID=14562420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11148478A Granted JPS5538325A (en) 1978-09-11 1978-09-11 4-anilinoquinazoline derivative and its preparation

Country Status (13)

Country Link
US (2) US4322420A (en:Method)
JP (1) JPS5538325A (en:Method)
BE (1) BE878723A (en:Method)
CA (1) CA1151168A (en:Method)
CH (1) CH642361A5 (en:Method)
DE (1) DE2936705A1 (en:Method)
DK (1) DK377079A (en:Method)
ES (1) ES8100276A1 (en:Method)
FR (1) FR2435248A1 (en:Method)
GB (1) GB2033894B (en:Method)
IT (1) IT1119933B (en:Method)
NL (1) NL7906761A (en:Method)
SE (1) SE446337B (en:Method)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
JP2676082B2 (ja) * 1987-12-25 1997-11-12 住友化学工業株式会社 ゴキブリ防除用マイクロカプセル剤
EP0584222B1 (en) * 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5733561A (en) * 1991-06-12 1998-03-31 Mitsui Toatsu Chemicals, Incorporated Insecticide composition and production process thereof
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5234936A (en) * 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
AU739382B2 (en) * 1993-12-10 2001-10-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6214987B1 (en) 1994-09-02 2001-04-10 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
US6232465B1 (en) 1994-09-02 2001-05-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
TW321649B (en:Method) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (ko) * 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
EP1082311A1 (en) 1998-05-28 2001-03-14 Parker Hughes Institute Quinazolines for treating brain tumor
US6800649B1 (en) * 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
WO2001032651A1 (en) 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
NZ532524A (en) * 2001-11-03 2007-02-23 Astrazeneca Ab Quinazoline derivatives as antitumor agents
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005028470A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
PT1667992E (pt) 2003-09-19 2007-04-30 Astrazeneca Ab Derivados de quinazolina
CA2540008A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
JP2007509985A (ja) * 2003-10-31 2007-04-19 ニューロジェン・コーポレーション カプサイシン受容体作動薬
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1993349A (zh) * 2004-06-04 2007-07-04 阿斯利康(瑞典)有限公司 作为erbb受体酪氨酸激酶的喹唑啉衍生物
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
ATE521603T1 (de) 2005-02-26 2011-09-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
EP1940825A1 (en) * 2005-09-20 2008-07-09 Astra Zeneca AB Quinazoline derivatives as anticancer agents
JP2009517450A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
DE602006009304D1 (de) * 2005-12-02 2009-10-29 Astrazeneca Ab Chinazoleinderivate
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8246966B2 (en) * 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8338433B2 (en) * 2006-11-22 2012-12-25 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetoplastid agents
AU2008212999A1 (en) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
BRPI0907916A2 (pt) * 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
CA2723989C (en) 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN104208718B (zh) 2009-02-20 2017-12-29 2-Bbb医疗股份有限公司 基于谷胱甘肽的药物递送系统
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN110372666B (zh) * 2018-04-13 2022-11-08 华东理工大学 喹唑啉类化合物作为egfr三突变抑制剂及其应用
JP7474269B2 (ja) * 2019-03-15 2024-04-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1724086A (en) * 1929-08-13 Eentrich astd max hardtmankt
US2794018A (en) * 1953-08-07 1957-05-28 New quinazoline derivatives
CH492395A (de) * 1966-04-26 1970-06-30 Sandoz Ag Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels
US3560619A (en) * 1967-01-03 1971-02-02 Mead Johnson & Co Aminoquinazolines and quinazolones in treatment of coccidiosis
US3702849A (en) * 1967-10-26 1972-11-14 Pfizer 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
US4041030A (en) * 1973-09-20 1977-08-09 Delalande S.A. Arylamino pyrimidinic derivatives
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation

Also Published As

Publication number Publication date
IT7968794A0 (it) 1979-09-10
ES484097A0 (es) 1980-11-01
JPS5538325A (en) 1980-03-17
GB2033894A (en) 1980-05-29
NL7906761A (nl) 1980-03-13
IT1119933B (it) 1986-03-19
US4322420A (en) 1982-03-30
SE7907493L (sv) 1980-03-12
GB2033894B (en) 1983-02-16
DE2936705A1 (de) 1980-03-20
US4464375A (en) 1984-08-07
FR2435248A1 (fr) 1980-04-04
FR2435248B1 (en:Method) 1983-02-18
DK377079A (da) 1980-03-12
BE878723A (fr) 1980-03-11
ES8100276A1 (es) 1980-11-01
SE446337B (sv) 1986-09-01
CH642361A5 (de) 1984-04-13
CA1151168A (en) 1983-08-02

Similar Documents

Publication Publication Date Title
JPS626546B2 (en:Method)
EP0005528B1 (en) Imidazole derivatives, their preparation and pharmaceutical compositions
US4855298A (en) 6-Halo-1,2,3,4-tetrahydroquinazoline-4-spiro-4-imidazolidine-2,2'5'-triones useful for the treatment and prophylaxis of diabetic complications
JPS609713B2 (ja) カルボスチリル誘導体
JPS6364428B2 (en:Method)
JPH0415786B2 (en:Method)
JP3939246B2 (ja) インドロキナゾリノン類
JPH01104069A (ja) １−［（２−ピリミジニアル）アミノアルキル］ピペリジン類、その製造方法およびその医薬への応用
JPH0283375A (ja) ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
JPH02138266A (ja) ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体
JPH0466B2 (en:Method)
JPS6047255B2 (ja) ２−アミノ−５−スルフアモイル−安息香酸アミドの製法
JPS5973579A (ja) ベンゾフラン又はベンゾチオフェン誘導体，この化合物を有効成分とする尿酸排泄剤及びその製造方法
JPS58146569A (ja) イミダゾリジン誘導体
JPH05117243A (ja) ２−アミノピリミジン−４−カルボキサミド誘導体、その製造と治療における応用
JPH0559117B2 (en:Method)
JPS626715B2 (en:Method)
KR20100103532A (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JPS6399057A (ja) グリシン誘導体
JPH0625191B2 (ja) １−［２−（フエニルメチル）フエニルピペラジン化合物、その製造方法および医薬組成物
JPH0710863B2 (ja) エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用
JPH05247052A (ja) Ｎ−アルキルグルタールイミドの４−（４−ピペリジニル）−チエノ〔３，２−ｃ〕ピリジン誘導体
JPH0436156B2 (en:Method)
EP0581767B1 (en) 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS
JPS5855138B2 (ja) ホウコウゾクカルボンサンアミドユウドウタイノセイゾウホウホウ